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Abstract
Background: Head and neck squamous cell carcinomas (HNSCC) have been causally associated
with tobacco and alcohol exposure. However, 10–15% of HNSCC develop in absence of significant
carcinogen exposure. Several lines of evidence suggest that the genetic composition of HNSCC
varies based on the extent of tobacco/alcohol exposure, however, no genome wide measures have
been applied to address this issue. We used comparative genomic hybridization (CGH) to screen
for the genetic aberrations in 71 patients with head and neck squamous cell carcinoma and stratified
the findings by the status of tobacco/alcohol exposure.
Results: Although the median number of abnormalities (9), gains (6) and losses (2) per case and
the overall pattern of abnormalities did not vary significantly by the extent of tobacco/alcohol
exposure, individual abnormalities segregating these patients were identified. Gain of 1p (p = 0.03)
and 3q amplification (p = 0.05) was significantly more common in patients with a history of tobacco/
alcohol exposure.
Conclusions: This data suggests that the overall accumulated chromosomal aberrations in head
and neck squamous cell carcinoma are not significantly influenced by the severity of tobacco/alcohol
exposure with limited exceptions.
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Background
A causal association between squamous cell carcinoma
arising in the head and neck region (HNSCC) and expo-
sure to tobacco and alcohol is well established [1–3].
However, 10–15% HNSCC occur in patients without any
antecedent history of tobacco or alcohol exposure [4,5].
Several studies have suggested that these patients have a
divergent clinical course compared to patients with tobac-
co associated HNSCC, which may be a reflection of differ-
ences in the genetic composition [4–6]. Empiric evidence
suggesting that non-smokers may respond differently to
carcinogenic insults is offered in a report by Schantz et al.,
showing the highest levels of chromosomal sensitivity in
lymphocytes after exposure to the clastogen bleomycin in
HNSCC patients who were non-smokers [7]. Relatively
few studies have directly investigated the impact of tobac-
co/alcohol exposure on the genetic composition of HN-
SCC. Amplification and expression of cyclin D1, p53
mutation and deletions of 3p, 5q, and 9p21 are suggested
to be influenced by the degree of tobacco exposure [4,6,8].
The largest effort on this topic has been reported by Koch
and colleagues, who found significantly higher rates of
p53 mutation and loss of heterozygosity at 3p, 4q, and
11q as part of allelotyping analysis of 10 individual loci
[4]. No studies have utilized true genome-wide evaluative
measures to analyze the impact of carcinogen exposure on
the accumulated chromosomal abnormalities in HNSCC.
Comparative genomic hybridization (CGH), originally
described by Kallionemi in 1992, is an ideal screening
measure, allowing the simultaneous detection of gains,
losses and amplifications in genetic information in an in-
dividual tumor [9]. In addition, several authors have used
the total number of chromosomal abnormalities as an as-
sessment of genomic instability [10]. In this study, CGH
analysis showed the presence of significant overlap in ge-
nomic instability and in the individual chromosomal ab-
normalities based on the degree of tobacco/alcohol
exposure in HNSCC, with the exception of gains/amplifi-
cations at 3q and 1p.
Results and Discussion
The study population was divided into 15 (21%) patients
with limited and 56 patients (79%) with a significant to-
bacco/alcohol exposure history. Of the 15 patients in low-
level tobacco/alcohol exposure group, 13 patients gave no
history of tobacco usage, while 10 patients gave no history
of alcohol exposure. Of the two patients with tobacco ex-
posure histories, one gave a history of smoking less than
2 packs of cigarettes in her lifetime and the other had a
history of smoking 0.5 pack years, 51 years prior to pres-
entation with cancer. Although patients without signifi-
cant tobacco/alcohol exposure were younger in age, there
was no significant difference in all other clinical, tumor,
treatment and outcome characteristics (Table 1). The dif-
ference in age based on the severity of tobacco/alcohol ex-
posure has been previously described [4,7].
Table 1: Differences in clinical, pathological, and CGH findings by status of carcinogen exposure.
Overall Tobacco/Alcohol (-) Tobacco/Alcohol (+) p-value
Median age 61 years 53 years 64.5 years .002A
Male gender (n, %) 47 (66%) 10 (67%) 37 (66%) NSB
TNM Stage (n, %)
I-II 17 (24%) 3 (20%) 14 (25%) NSB
III-IV 54 (76%) 12(80%) 42 (75%)
Nodal metastasis at presentation 37 (52%) 7 (47%) 30 (54%) NSA
Treatment (n, %)
Surgery based 36 (51%) 8 (53%) 28 (50%) NSA
Radiation based 35 (49%) 7 (47%) 28 (50%)
Second primary cancers 8 (11%) 2 (13%) 6 (11%) NSB
Median follow-up (months) 38 47 months 38 months NSA
Recurrence (n, %) 24 (34%) 7 (47%) 17 (30%) NSB
Death- from cancer 18 (25%) 4 (27%) 14 (25%) NSB
Death- any cause 26 (36%) 6 (40%) 20 (36%) NSB
3 year disease free survival 55% 47% 58% NSD
3-year cause specific survival 72% 81% 69% NSD
3-year overall survival 65% 67% 64% NSD
Median # of gains* 6 4 6 NSB
Median # of losses* 2 3 2 NSB
Median # of abnormalities* 9 8 9 NSB
*Determined by calculation of individual, continuous chromosomal gains, losses and amplifications identified by CGH analysis. A Mann-Whitney U 
test B Fisher's exact test C Chi Square D Log rank testBMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/22
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The median number of copy number abnormalities was 9
per case, ranging from 0 to 27. The most common sites for
gains were 1p, 3q, 5p, 6p, and 11q, losses 3p, 4q, and 13q,
and amplifications 3q25-27, 11q13 and 8q24-qter (Figure
1). These results are congruent with those reported in the
literature for CGH analysis of HNSCC [11–14]. The level
of genomic instability, measured by the median number
of continuous copy number changes by CGH analysis was
also not influenced by the severity of carcinogen exposure.
These findings are in contrast to allelotyping studies,
which show higher rates of abnormalities in patients with
significant tobacco/alcohol exposure [4]. Since tobacco is
known to cause single strand breaks, it may be aberrant re-
pair of these changes that is detected by LOH, which are
below the threshold of detection by CGH.
Although the total number and general pattern of abnor-
malities were similar, the prevalence of individual abnor-
malities was different based on the extent of tobacco/
alcohol exposure as outlined in Figure 2. Amplification at
3q26-27 (p = 0.05) and gain of 1p (p = 0.03) were signif-
icantly more common in patients with carcinogen expo-
sure. A high prevalence of 3q amplification has been
reported in many studies on tobacco-associated cancers,
including those of the lung, cervix and esophagus [11,13–
17]. We and others have shown that PIK3CA is a candidate
oncogene at 3q in these tumors [12,18,19]. Interestingly,
PI3K pathway has been suggested to play a role in modu-
lating the effects of benzopyrene, a tobacco-derived car-
cinogen, and its metabolite, anti-7,8-dihydroxy-9,10-
epoxy-7,8,9,10-terahydrobenzopyrene [20].
Although less frequent, 1p gains are also common to
many tobacco-associated malignancies [11,13–16]. Work
by Racz and colleagues suggest that PAX7 and ENO1 may
be candidate oncogenes in this region [21]. PAX7 is part
of a family of transcription factors known to be carcino-
genic. Evidence suggests that gain of function in PAX7 trig-
gers neoplastic development by maintaining cells in a
deregulated, undifferentiated and proliferative state, as is
seen in alveolar rhabdomyosarcomas. Loss of 6p was an
event unique to patients with no tobacco/alcohol expo-
sure. This site may contain a factor protecting cells from
tobacco induced carcinogenesis, including genes such as
MSH1, a gene involved in mismatch repair [22].
Conclusions
Several limitations must be taken into account when as-
sessing this work. First, the retrospective nature of the data
collection introduces inherent biases. Second, although it
is amongst the largest studies analyzing of genetic differ-
ences based on carcinogen exposure, the sample size re-
mains small limiting statistical power to detect existing
differences. Finally, CGH is limited in resolution to copy
number abnormalities >5 Kb, making it likely that smaller
aberrations may exist that are influenced by tobacco/alco-
hol exposure. Taking the limitations into account, we
identified no differences in the degree of chromosomal in-
stability and significant overlap in the pattern of chromo-
somal aberrations occurring in patients with HNSCC
divided by the severity of tobacco/alcohol exposure. How-
ever, several individual differences exist, including ampli-
fication of 3q and gain of 1p, which may represent specific
sites of damage by tobacco/alcohol carcinogens. Further
work is required to refine the finding of this study and un-
derstand its implications.
Methods
Tissue aquisition and clinical information
Tumor samples from patients undergoing curative treat-
ment for HNSCC were obtained at time of biopsy or sur-
gical resection in the operating room, following
guidelines established by the Institutional Review Board.
Only patients with previously untreated HNSCC were in-
cluded in this study. All samples were analyzed histologi-
cally to confirm the presence of >70% carcinoma. The
study population included 71 patients ranging in age
from 38 to 89 years (median- 61 years). There was a pre-
dominance of males (66%). The oral cavity (17%) and
laryngopharynx (83%) were the most common primary
sites. Overall, 36 (51%) patients were treated surgically,
with adjuvant radiation utilized for patients with ad-
vanced TNM stage (4 cases) or extracapsular extension
pathologically identified in nodal metastasis (2 patients).
Radiation alone was utilized in 35 patients and in combi-
nation with chemotherapy in 33 patients. The median fol-
low-up for the study population was 38 months, ranging
from 2–109 months.
Tobacco usage was assessed in pack-years, defined by the
number of packs of cigarettes smoked daily multiplied by
the number of years of active smoking. For the purposes
of this analysis, smoking 4 hand rolled cigarettes, 4 cigars,
or 4 pipes full of tobacco was considered equivalent to
smoking 1 pack of industrial cigarettes. Tobacco usage was
coded as a dichotomous variable, and was considered
positive if a greater than 2-pack year smoking history was
reported. Alcohol consumption was also recorded as a di-
chotomous variable, and was considered positive when
daily usage of two alcohol equivalents on a daily basis or
binge alcohol usage (repetitive use of >5 alcohol equiva-
lents at a single sitting) was reported. For the purpose of
this study, patients were divided into two groups based on
the history of carcinogen exposure. Group 1 had a limited
or no history of tobacco and/or alcohol exposure, while
group 2 patients reported significant tobacco and/or alco-
hol exposure.
Outcome of treatment was evaluated on the date of last
patient contact by determining the presence or absence ofBMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/22
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Figure 1
Ideogram showing DNA copy number changes identified by CGH analysis of primary tumors derived from patients with head
and neck cancer with (A) and without (B) tobacco/alcohol exposure. Caption: Thin vertical lines on either side of the ideogram
indicate losses (left) and gains (right) of the chromosomal region. The chromosomal regions of the high-level amplification are
shown by thick lines (right).BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/22
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Figure 2
Chromosomal abnormalities detected segregating patients based on the status of alcohol exposure. Gains (A), amplifications
(B) and losses (C) are shown separately. * Indicates statistically significant differences (P < 0.05)BMC Genetics 2002, 3 http://www.biomedcentral.com/1471-2156/3/22
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cancer and the vital status (alive, dead, or unknown). The
date and location of the first recurrence was ascertained.
For patients who died, the cause of death was determined
from review of the death certificate, physicians' death
summary, and/or tumor registry records. Disease-free sur-
vival was determined as the differences between time zero
(date of first treatment) and the date of first recurrence.
Cause-specific survival was the difference between time
zero and the date of death due to cancer.
Comparative genomic hybridization
CGH was performed using previously published methods
[11]. Seven to 10 separate metaphases were captured and
processed using the Quantitative Image Processing System
(Quips Pathvysion system, Applied Imaging, Santa Clara,
CA). Red, green, and blue fluorescence intensities were
analyzed for all metaphase spreads, normalized to a
standard length, and statistically combined to show the
red: green signal ratio and 95% confidence intervals for
the entire chromosome. Copy number changes were de-
tected based on the variance of the red: green ratio profile
from the standard of 1. Ratio values of 1.2 and 2.0 were
defined as thresholds for gains and amplifications, respec-
tively, and losses were defined as ratio of 0.8 or lower.
Statistical analysis
Statistical comparisons were performed using the JPM
software (SAS Institute, Inc., Cary, NC). Descriptive statis-
tics were used to summarize study data. Statistical signifi-
cance was accepted at a two-tailed p value of less than or
equal to 0.05. The p-value for accepting significance was
not adjusted for multiple comparisons. Non-parametric
qualitative and quantitative comparisons were performed
using Fisher's exact test and Kruskal-Wallis analysis of var-
iance, respectively. The Chi square test was utilized for
multi-group, qualitative comparisons. Survival data was
censored for patients lost to follow-up, surviving to the
end to the study, or dying of causes unrelated to cancer.
Survival curves were generated using the Kaplan-Meier
(product-limit) method to allow maximum use of cen-
sored observations. Survival comparisons were performed
using the log-rank test.
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